Advertisement
Screener

Telomir Pharmaceuticals, Inc. (TELO) EBITDA

Telomir Pharmaceuticals, Inc. (TELO) EBITDA

  • 2025-03-31: Basis Reported; EBITDA (m); Operating income $2.19M; Depreciation and amortization (m).
  • 2024-03-31: Basis Reported; EBITDA (m); Operating income $1.92M; Depreciation and amortization (m).

Historical EBITDA

EBITDA 3 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2025-03-31Reported(m)$2.19M(m)(m)(m)(m)-$863.13K(m)$337.00K(m)(m)
2024-03-31Reported(m)$1.92M(m)(m)(m)(m)-$1.94M(m)$804.02K(m)(m)

EBITDA 12 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lexaria Bioscience Corp. (LEXX)$0.084B-1.92
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)United States$0.086B
ONCOLYTICS BIOTECH INC (ONCY)$0.086B
Gain Therapeutics, Inc. (GANX)United States$0.080B-4.40
Rallybio Corp (RLYB)United States$0.089B
Lifevantage Corp (LFVN)United States$0.078B15.40
Adicet Bio, Inc. (ACET)United States$0.078B-0.81
Valion Bio, Inc. (VBIO)United States$0.077B
MAIA Biotechnology, Inc. (MAIA)United States$0.077B-2.30
iBio, Inc. (IBIO)United States$0.077B-2.94